Category: 2022 PR

Posted on / by Ante / in 2022 PR, 2024

Positive FDA Guidance for Phase III received for Revacept

Silver Springs, Maryland, and Martinsried, Germany, 07. August 2024: The U.S Food and Drug Association (FDA) has reviewed the preclinical and clinical development program for Revacept / PR-15 in a Type C meeting. Further on, the future clinical development program until market approval was presented and discussed with the FDA.

Posted on / by Ante / in 2022 PR

August 2022 – Revacept – Protects during carotid artery surgery

Good news from vascular medicine: the innovative drug Revacept can protect people with narrowed carotid arteries from both further strokes and dangerous bleeding. Thanks to this completely new dual efficacy, Revacept is ideal for preventing complications after stroke prevention surgery on narrowed carotid arteries. (…)